Lexeo Therapeutics, Inc. (LXEO)
(Delayed Data from NSDQ)
$12.10 USD
+0.41 (3.51%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $12.13 +0.03 (0.25%) 4:36 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LXEO 12.10 +0.41(3.51%)
Will LXEO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LXEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXEO
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
LXEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
Other News for LXEO
Buy Rating on Lexeo Therapeutics: Promising Clinical Advancements and Strategic FDA Engagement
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Taysha Gene Therapies (TSHA) and Lexeo Therapeutics, Inc. (LXEO)
Buy Rating for Lexeo Therapeutics Backed by Strong Finances and Promising Clinical Trials
Lexeo Therapeutics, Inc. (LXEO) Receives a Buy from RBC Capital
Buy Rating Affirmed for Lexeo Therapeutics Amid Anticipated Catalysts and Solid Financials